For SPMS, is HSCT better than any existing DMT? Maybe

[ActiveMSers]

Interesting take....

#ECTRIMS2021 – Stem Cell Transplant May Better Treat SPMS Than DMTs



by Marta Figueiredo PhD | October 15, 2021
SHARE THIS ARTICLE:

SHARE ARTICLE VIA EMAILCOPY ARTICLE LINK



Editor’s note: The Multiple Sclerosis News Today team is providing in-depth coverage of the virtual 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), Oct. 13–15. Go here to see the latest stories from the conference.

A patient-derived stem cell transplant is more effective than available disease-modifying therapies (DMTs) at slowing disease progression in people with active secondary progressive multiple sclerosis (SPMS), according to a real-life study in Italy.

https://multiplesclerosisnewstoday.c...ng-spms-study/

[ActiveMSers]

And maybe not....


Chapter

Autologous Hematopoietic Stem Cell Transplantation for Secondary Progressive Multiple Sclerosis

By Richard K. Burt, Basil Sharrack, Roumen Balabanov, John Rose, Xiaoqiang Han, Kathleen Quigley, Riccardo Saccardi
Book: Hematopoietic Stem Cell Transplantation and Cellular Therapies for Autoimmune Diseases

First Published 2021
Imprint CRC Press

ABSTRACT

Autologous hematopoietic stem cell transplantation (HSCT) is a form of immune suppressive/modulating therapy and, similar to other immune drugs, is largely ineffective in secondary progressive multiple sclerosis (SPMS). Future autologous HSCT studies performed in SPMS should be limited to SPMS with ongoing disease activity, have a control treatment arm, monitor brain and cervical cord atrophy, and utilize a conditioning regimen that does not increase early post-HSCT central nervous system atrophy as demonstrated on magnetic resonance (MRI).